News

VIVA, VIVA Physicians, Peripheral, Carotid Artery Device, clinical trial results

Viva Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announce clinical trial results and other new happenings at Viva '14, hosted in Las Vegas,...

The U.S. Food and Drug Administration (FDA) has cleared the Abbott family of Xience everolimus-eluting coronary stents for the additional indication to treat coronary chronic total occlusions (...

DAIC Editor Dave Fornell

The key take away messages from the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium were bioresorable stents and transcatheter valve technologies will likely...

Everflex stent, Covidien, ev3

The U.S Food and Drug Administration (FDA) cleared the EverFlex Self-Expanding Peripheral Stent System and outlined...

The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease....

October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus Premier Everolimus-Eluting Platinum...

Stenting Safe Effective Long-term Stroke Prevention

Using stents to keep neck arteries open is just as effective as invasive neck surgery for long-term prevention of fatal and disabling strokes, reports an international trial led by UCL (University...

“Once patients have survived cancer, they don't die from cancer, they die from heart disease. Cardio-oncology is about making sure that doesn't happen," said Juan Carlos Plana, M.D.

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a...

Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and feasibility of the company's Fortitude...

The Centers for Medicare & Medicaid Services (CMS) has determined that clinical sites that wish to participate in the newly announced CREST-2 carotid artery stenting (CAS) registry...

iFR

Earlier this year, the Barnes-Jewish Hospital at Washington University School of Medicine in St. Louis adopted the instant wave-Free Ratio (iFR) technology. The iFR modality is a pressure-derived...

September 26, 2014 — In response to new science showing that complete revascularization of all significantly blocked arteries leads to better outcomes in some heart attack patients, the American...

A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting stents (DP-SES) found that the...

Svelte Coronary DES DIRECT II Trial Six Month Results TCT 2014

Svelte Medical Systems reported that its drug-eluting coronary stent Integrated Delivery System (IDS) for percutaneous coronary intervention (PCI) met all DIRECT II study six-month angiographic...

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated...

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb...

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The...

Tryton Medical First U.S. Patient Extended Access Registry

Tryton Medical Inc. announced that the first patient in the United States has been enrolled in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. 

September 9, 2014 — Tryton Medical Inc. announced an initial closing of an aggregate $20 million private equity financing. Participating in this financing were existing investors RiverVest Venture...